The role of genetic factors and monocyte-to-osteoclast differentiation in the pathogenesis of Charcot neuroarthropathy. (August 2020)

• Record Type: Journal Article
• Authors: Kloska, Anna; Korzon-Burakowska, Anna; Malinowska, Marcelina; Bruhn-Olszewska, Bożena; Gabig-Cimińska, Magdalena; Jakóbkiewicz-Banecka, Joanna
• Is Part Of: Diabetes research and clinical practice. Volume 166(2020)
• Publication Date: 2020-08
• Subjects: Charcot foot -- Charcot neuroarthropathy -- RANKL -- OPG -- Osteoclast differentiation; Diabetes -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462
• DOI: 10.1016/j.diabres.2020.108337
• Languages: English
• ISSNs: 0168-8227

Abstract

Abstract: Charcot neuroarthropathy is a chronic, progressive condition of the skeletal system that affects some patients with diabetic neuropathy. It results in progressive destruction of bones of the foot and disorganisation of pedal joints and ligaments. Effective prevention and treatment for Charcot neuroarthropathy remain a challenge. Currently, there are no reliable repeatable markers to identify patients with diabetes who are at higher risk of developing Charcot neuroarthropathy. The pathogenesis underlying the development of Charcot neuroarthropathy also remains unclear. In this review, we provide an overview of the history, prevalence, symptoms, risk factors, diagnostics and treatment of Charcot neuroarthropathy. We also discuss the potential for OPG and RANKL gene variants to act as predictive markers for the development of Charcot neuroarthropathy. Finally, we summarise the latest research on the role of monocyte-to-osteoclast differentiation in the development of acute Charcot neuroarthropathy.